J. Nussberger

Publications436
h-index63
Citations14,757
Highly Influential Citations374
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • H. Brunner
  • 644 Publications, 23,433 Citations
  • B. Waeber
  • 780 Publications, 22,105 Citations
  • M. Burnier
  • 667 Publications, 16,544 Citations
  • J. Laragh
  • 576 Publications, 47,837 Citations
  • Publications
  • Influence
Angiotensin II Suppression in Humans by the Orally Active Renin Inhibitor Aliskiren (SPP100): Comparison With Enalapril
Renin is the main determinant of angiotensin (Ang) II levels. It, therefore, always appeared desirable to reduce Ang II levels by direct inhibition of renin. So far, specific renin inhibitors lacked… Expand
  • 384
  • 22
  • PDF
Aliskiren, a Novel Orally Effective Renin Inhibitor, Provides Dose-Dependent Antihypertensive Efficacy and Placebo-Like Tolerability in Hypertensive Patients
Background—Stopping the detrimental effects of the renin-angiotensin system at the most upstream point of the cascade offers theoretical advantages for cardiovascular protection. This study compares… Expand
  • 492
  • 17
  • PDF
Renin inhibition with aliskiren: where are we now, and where are we going?
With the development of aliskiren, blockade of the renin-angiotensin-aldosterone system (RAAS) at the level of the interaction of renin with a substrate has become a clinical reality. This review… Expand
  • 251
  • 15
Plasma bradykinin in angio-oedema
BACKGROUND Bradykinin is believed to be the main mediator of symptoms in hereditary (HA) and acquired (AA) angio-oedema due to C1 esterase inhibitor deficiency, as well as in angio-oedema that… Expand
  • 625
  • 14
Blood Pressure Lowering in Essential Hypertension With an Oral Renin Inhibitor, Aliskiren
Abstract—Inhibition of the first and rate-limiting step of the renin-angiotensin system has long been an elusive therapeutic goal. Aliskiren, the first known representative of a new class of… Expand
  • 344
  • 14
  • PDF
Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability.
BACKGROUND Patients with an activated renin-angiotensin system (RAS) or genetic alterations of the RAS are at increased risk of myocardial infarction (MI). Administration of ACE inhibitors reduces… Expand
  • 651
  • 12
  • PDF
Activity assays and immunoassays for plasma Renin and prorenin: information provided and precautions necessary for accurate measurement.
BACKGROUND Measurement of plasma renin is important for the clinical assessment of hypertensive patients. The most common methods for measuring plasma renin are the plasma renin activity (PRA) assay… Expand
  • 146
  • 12
  • PDF
Aldosterone Synthase Inhibitor Ameliorates Angiotensin II–Induced Organ Damage
Background—Aldosterone and angiotensin (Ang) II both may cause organ damage. Circulating aldosterone is produced in the adrenals; however, local cardiac synthesis has been reported. Aldosterone… Expand
  • 166
  • 9
Bradykinin and the pathophysiology of angioedema.
Angioedema has different causes and different clinical presentations. Some types of angioedema may be mediated by bradykinin. We measured plasma levels of bradykinin-(1-9)nonapeptide by… Expand
  • 201
  • 9
Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers.
The purpose of this study was to assess the inhibitory effect of TCV-116, an orally active angiotensin II (Ang II) antagonist, on the pressor action of exogenous Ang II and to determine the… Expand
  • 99
  • 9